Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Q34642874)

3 August 2017

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (English)

1 reference

ESMO Guidelines Working Group

3 August 2017

6

object named as

ESMO Guidelines Working Group

1 reference

3 August 2017

R Dummer

1

1 reference

3 August 2017

A Hauschild

2

1 reference

3 August 2017

M Guggenheim

3

1 reference

3 August 2017

U Keilholz

4

1 reference

3 August 2017

G Pentheroudakis

5

1 reference

3 August 2017

1 October 2012

1 reference

3 August 2017

1 reference

3 August 2017

23 Suppl 7

1 reference

3 August 2017

vii86-91

1 reference

Melanoma incidence and mortality in Scotland 1979-2003.

3 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Reduced melanoma after regular sunscreen use: randomized trial follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Sinonasal, genital and acrolentiginous melanomas show distinct characteristics of KIT expression and mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Sentinel-node biopsy or nodal observation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Role of radiation therapy in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

The conundrum of follow-up: should it be abandoned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS229

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS229

1 reference

3 August 2017

1 reference